CTOs on the Move

Liquidia Technologies

www.liquidia.com

 
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.liquidia.com
  • PO Box 110085
    Research Triangle Park, NC USA 27709
  • Phone: 919.328.4400

Executives

Name Title Contact Details

Funding

Liquidia Technologies raised $22.4M on 12/26/2019

Similar Companies

Sonde Health

Sonde Health is a digital medicine company developing a voice-based technology platform with the potential to transform the way we monitor and diagnose mental and physical health.

Kosan Biosciences

Kosan Biosciences Incorporated is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stone Clinical Laboratories

The most innovative, patient and provider focused preventative diagnostic laboratory in the industry

Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting.

Shattuck Labs

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck`s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company`s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.